The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list. Among them Huntington’s disease (HD) is the most widespread.
Currently, the standard of care of such disorders is focused on symptomatic treatments as no effective therapeutic interventions aimed at the treatment or prevention of polyQ diseases exist. This calls for an urgent need of innovative therapeutic strategies.
We have identified a number of novel therapeutic factors capable of reducing the toxicity of mutated proteins causing polyQ diseases. Their administration to both in vitro and in vivo model systems of HD via state-of-the-art gene therapy delivery systems resulted in amelioration of the detrimental effects of the mutant HTT gene, i.e., in reduced cell death, oxidative stress, transcriptional alterations, and alleviated motor deficit.

TRL (Technology Readiness Level)

TRL 3/4 / 9

Inventors

Martello
Graziano

Ferlazzo
Giorgia
Maria

Gambetta
Anna
Maria

Leeb
Martin

Download the brochure

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high[...]

  • Use of small molecules to rescue folding defective proteins

    The use of CFTR (cystic fibrosis transmembrane conductance regulator) correctors for the treatment of rare and devastating genetic muscular diseases, namely sarcoglycanopathies and Brody myopathy, is the object of this invention. Sarcoglycanopathies and Brody myopathy are rare inherited striated muscle[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation